These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 33426095)

  • 1. Development of an Immunoassay for the Detection of Amyloid Beta 1-42 and Its Application in Urine Samples.
    Wongta A; Hongsibsong S; Chantara S; Pattarawarapan M; Sapbamrer R; Sringarm K; Xu ZL; Wang H
    J Immunol Res; 2020; 2020():8821181. PubMed ID: 33426095
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Preanalytical approaches to improve recovery of amyloid-β peptides from CSF as measured by immunological or mass spectrometry-based assays.
    Schauer SP; Mylott WR; Yuan M; Jenkins RG; Rodney Mathews W; Honigberg LA; Wildsmith KR
    Alzheimers Res Ther; 2018 Nov; 10(1):118. PubMed ID: 30486870
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A digital enzyme-linked immunosorbent assay for ultrasensitive measurement of amyloid-β 1-42 peptide in human plasma with utility for studies of Alzheimer's disease therapeutics.
    Song L; Lachno DR; Hanlon D; Shepro A; Jeromin A; Gemani D; Talbot JA; Racke MM; Dage JL; Dean RA
    Alzheimers Res Ther; 2016 Dec; 8(1):58. PubMed ID: 27978855
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Highly specific and ultrasensitive plasma test detects Abeta(1-42) and Abeta(1-40) in Alzheimer's disease.
    Thijssen EH; Verberk IMW; Vanbrabant J; Koelewijn A; Heijst H; Scheltens P; van der Flier W; Vanderstichele H; Stoops E; Teunissen CE
    Sci Rep; 2021 May; 11(1):9736. PubMed ID: 33958661
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Amyloid-β 42/40 cerebrospinal fluid concentration ratio in the diagnostics of Alzheimer's disease: validation of two novel assays.
    Lewczuk P; Lelental N; Spitzer P; Maler JM; Kornhuber J
    J Alzheimers Dis; 2015; 43(1):183-91. PubMed ID: 25079805
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of ELISA- and SIMOA-based quantification of plasma Aβ ratios for early detection of cerebral amyloidosis.
    De Meyer S; Schaeverbeke JM; Verberk IMW; Gille B; De Schaepdryver M; Luckett ES; Gabel S; Bruffaerts R; Mauroo K; Thijssen EH; Stoops E; Vanderstichele HM; Teunissen CE; Vandenberghe R; Poesen K
    Alzheimers Res Ther; 2020 Dec; 12(1):162. PubMed ID: 33278904
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evaluation of the cerebrospinal fluid amyloid-β1-42/amyloid-β1-40 ratio measured by alpha-LISA to distinguish Alzheimer's disease from other dementia disorders.
    Nutu M; Zetterberg H; Londos E; Minthon L; Nägga K; Blennow K; Hansson O; Ohrfelt A
    Dement Geriatr Cogn Disord; 2013; 36(1-2):99-110. PubMed ID: 23860354
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Quantum dots-based sandwich immunoassay for sensitive detection of Alzheimer's disease-related Aβ
    Tang M; Pi J; Long Y; Huang N; Cheng Y; Zheng H
    Spectrochim Acta A Mol Biomol Spectrosc; 2018 Aug; 201():82-87. PubMed ID: 29734108
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Development of a Novel Urine Alzheimer-Associated Neuronal Thread Protein ELISA Kit and Its Potential Use in the Diagnosis of Alzheimer's Disease.
    Ma L; Wang R; Han Y; Sheng S; Zhu J; Ji Z; Zhao Z; Cao Z; Wang P
    J Clin Lab Anal; 2016 Jul; 30(4):308-14. PubMed ID: 26037289
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Quantitative analysis of amyloid beta peptides in cerebrospinal fluid of Alzheimer's disease patients by immunoaffinity purification and stable isotope dilution liquid chromatography/negative electrospray ionization tandem mass spectrometry.
    Oe T; Ackermann BL; Inoue K; Berna MJ; Garner CO; Gelfanova V; Dean RA; Siemers ER; Holtzman DM; Farlow MR; Blair IA
    Rapid Commun Mass Spectrom; 2006; 20(24):3723-35. PubMed ID: 17117458
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Amyloid beta peptides in plasma in early diagnosis of Alzheimer's disease: A multicenter study with multiplexing.
    Lewczuk P; Kornhuber J; Vanmechelen E; Peters O; Heuser I; Maier W; Jessen F; Bürger K; Hampel H; Frölich L; Henn F; Falkai P; Rüther E; Jahn H; Luckhaus Ch; Perneczky R; Schmidtke K; Schröder J; Kessler H; Pantel J; Gertz HJ; Vanderstichele H; de Meyer G; Shapiro F; Wolf S; Bibl M; Wiltfang J
    Exp Neurol; 2010 Jun; 223(2):366-70. PubMed ID: 19664622
    [TBL] [Abstract][Full Text] [Related]  

  • 12. SERS-Based Immunoassay Enhanced with Silver Probe for Selective Separation and Detection of Alzheimer's Disease Biomarkers.
    Yu D; Yin Q; Wang J; Yang J; Chen Z; Gao Z; Huang Q; Li S
    Int J Nanomedicine; 2021; 16():1901-1911. PubMed ID: 33707945
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Performance Evaluation of an Automated ELISA System for Alzheimer's Disease Detection in Clinical Routine.
    Chiasserini D; Biscetti L; Farotti L; Eusebi P; Salvadori N; Lisetti V; Baschieri F; Chipi E; Frattini G; Stoops E; Vanderstichele H; Calabresi P; Parnetti L
    J Alzheimers Dis; 2016 Jul; 54(1):55-67. PubMed ID: 27447425
    [TBL] [Abstract][Full Text] [Related]  

  • 14. CSF amyloid-beta-peptides in Alzheimer's disease, dementia with Lewy bodies and Parkinson's disease dementia.
    Bibl M; Mollenhauer B; Esselmann H; Lewczuk P; Klafki HW; Sparbier K; Smirnov A; Cepek L; Trenkwalder C; Rüther E; Kornhuber J; Otto M; Wiltfang J
    Brain; 2006 May; 129(Pt 5):1177-87. PubMed ID: 16600985
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Proteomics-derived cerebrospinal fluid markers of autopsy-confirmed Alzheimer's disease.
    Roher AE; Maarouf CL; Sue LI; Hu Y; Wilson J; Beach TG
    Biomarkers; 2009 Nov; 14(7):493-501. PubMed ID: 19863188
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Isobaric Quantification of Cerebrospinal Fluid Amyloid-β Peptides in Alzheimer's Disease: C-Terminal Truncation Relates to Early Measures of Neurodegeneration.
    Rogeberg M; Almdahl IS; Wettergreen M; Nilsson LN; Fladby T
    J Proteome Res; 2015 Nov; 14(11):4834-43. PubMed ID: 26452689
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Impact of cerebrospinal fluid matrix on the detection of Alzheimer's disease with Aβ42 and influence of disease on the total-Aβ42/Aβ40 ratio.
    Slemmon JR; Shapiro A; Mercken M; Streffer J; Romano G; Andreasen N; Zetterberg H; Blennow K
    J Neurochem; 2015 Dec; 135(5):1049-58. PubMed ID: 26332787
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Establishing In-House Cutoffs of CSF Alzheimer's Disease Biomarkers for the AT(N) Stratification of the Alzheimer Center Barcelona Cohort.
    Orellana A; García-González P; Valero S; Montrreal L; de Rojas I; Hernández I; Rosende-Roca M; Vargas L; Tartari JP; Esteban-De Antonio E; Bojaryn U; Narvaiza L; Alarcón-Martín E; Alegret M; Alcolea D; Lleó A; Tárraga L; Pytel V; Cano A; Marquié M; Boada M; Ruiz A
    Int J Mol Sci; 2022 Jun; 23(13):. PubMed ID: 35805894
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cerebrospinal fluid amyloid beta peptide patterns in Alzheimer's disease patients and nondemented controls depend on sample pretreatment: indication of carrier-mediated epitope masking of amyloid beta peptides.
    Bibl M; Esselmann H; Otto M; Lewczuk P; Cepek L; Rüther E; Kornhuber J; Wiltfang J
    Electrophoresis; 2004 Sep; 25(17):2912-8. PubMed ID: 15349929
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Short amyloid-beta (Abeta) immunogens reduce cerebral Abeta load and learning deficits in an Alzheimer's disease mouse model in the absence of an Abeta-specific cellular immune response.
    Maier M; Seabrook TJ; Lazo ND; Jiang L; Das P; Janus C; Lemere CA
    J Neurosci; 2006 May; 26(18):4717-28. PubMed ID: 16672644
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.